PYC Therapeutics (ASX:PYC) Insider Ownership: 0.00 % (As of Aug. 06, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ASX:PYC PYC Therapeutics Ltd ASX:PYC
28 GF Score
Price A$2.13
! 2 Warning Signs
View Full Analysis

What is PYC Therapeutics Insider Ownership?

PYC Therapeutics ASX:PYC +1.43% 28 Insider Ownership is 0.00 % as of Aug. 06, 2026. GuruFocus rates ASX:PYC with a GF Score™ of 28/100. The stock has 2 warning signs investors should review.

Insider ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, PYC Therapeutics's insider ownership is 0.00%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, PYC Therapeutics's Institutional Ownership is 10.37%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, PYC Therapeutics's Float Percentage Of Total Shares Outstanding is 0.00%.

PYC Therapeutics Insider Ownership Historical Data

* Premium members only.

The historical data trend for PYC Therapeutics's Insider Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PYC Therapeutics Insider Ownership Chart

PYC Therapeutics Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Insider Ownership
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

PYC Therapeutics Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Insider Ownership Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
ASX:PYC
28GF Score
PYC Therapeutics Ltd ASX:PYC
Insider Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

PYC Therapeutics Insider Ownership Calculation

The percentage of shares that are owned by company insiders relative to the total shares outstanding.

Frequently Asked Questions Learn more about Insider Ownership →
What does a Insider Ownership of 0.00 % mean?
PYC Therapeutics (ASX:PYC) has a Insider Ownership of 0.00 % as of Aug. 06, 2026. Insider ownership equals the percent of shares owned by company insiders relative to total shares. View historical data on PYC Therapeutics and its competitors.
Is PYC Therapeutics' Insider Ownership too high?
PYC Therapeutics' current Insider Ownership is 0.00 %. Overall, PYC Therapeutics has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does PYC Therapeutics' Insider Ownership compare to VRTX and REGN?
PYC Therapeutics' Insider Ownership of 0.00 % can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Insider Ownership for a Biotechnology company?
A good Insider Ownership depends on the Biotechnology industry context. However, Insider Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Insider Ownership mean?
A high Insider Ownership can signal that a stock is expensive relative to its fundamentals. Insider ownership equals the percent of shares owned by company insiders relative to total shares. View historical data on PYC Therapeutics and its competitors. PYC Therapeutics's current Insider Ownership is 0.00 %. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PYC Therapeutics stock overvalued right now?
PYC Therapeutics (ASX:PYC) has a current Insider Ownership of 0.00 %. The current Insider Ownership is 0.00 %. PYC Therapeutics' overall GF Score™ is 28/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Insider Ownership calculated?
Insider Ownership is calculated from a company's financial statements. For PYC Therapeutics (ASX:PYC), the current Insider Ownership is 0.00 % as of Aug. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

PYC Therapeutics Business Description

Other Exchanges PYCXF:USA
Address 6 Verdun Street, Harry Perkins Institute of Medical Research, Nedlands, Perth, WA, AUS, 6009
PYC Therapeutics Ltd is an RNA therapeutics drug development company, leveraging a proprietary delivery platform to solve the challenges in RNA therapeutics - safe and effective delivery of the drug inside the cell. The company's principal business activity is of of drug development and progressing the company's drug pipeline through preclinical and clinical development. Geographically, it operates only in Australia.
28GF Score

Get the complete analysis for ASX:PYC

Insider Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$2.13
Price